5H-Dibenz[b,f]azepine-5-propanamine,3-chloro-10,11-dihydro-N,N-dimethyl- cas no:303-49-1
Synonyms: 5H-Dibenz[b,f]azepine,3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro- (6CI,7CI,8CI);3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine;Chlorimipramine;G 34586;NSC 169865;
Name5H-Dibenz[b,f]azepine-5-propanamine,3-chloro-10,11-dihydro-N,N-dimethyl-
CAS303-49-1
Synonyms5H-Dibenz[b,f]azepine,3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro- (6CI,7CI,8CI);3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine;Chlorimipramine;G 34586;NSC 169865;
EINECS(EC#)206-144-2
Molecular FormulaC19H23ClN2
Molecular Weight314.85
Appearancewhite to off-white powder
refractive index1.581
Hazard Xn: Harmful;
Risk R20/21/22
Safety
Hazard Codes : Xn .gif)
Risk Statements: 20/21/22
20/21/22 : 3-(9-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine hydrochloride (303-49-1 ) is harmful by inhalation, in contact with skin and if swallowed .
Safety Statements : 36
36: Keep away from sources of ignition - No smoking
WGK Germany: 3
RTECS: HN9055000
|
Organism
|
Test Type
|
Route
|
Reported Dose (Normalized Dose)
|
Effect
|
Source
|
|
man
|
TDLo
|
oral
|
357ug/kg (0.357mg/kg)
|
gastrointestinal: nausea or vomiting
|
Journal of Clinical Pyschopharmacology. Vol. 2, Pg. 215, 1982.
|
|
mouse
|
LD50
|
intraperitoneal
|
150mg/kg (150mg/kg)
|
|
Journal of Medicinal Chemistry. Vol. 21, Pg. 448, 1978.
|
|
mouse
|
LD50
|
intravenous
|
27mg/kg (27mg/kg)
|
|
Acta Pharmaceutica Suecica. Vol. 13, Pg. 485, 1976.
|
|
mouse
|
LD50
|
oral
|
380mg/kg (380mg/kg)
|
behavioral: wakefulness
behavioral: changes in motor activity (specific assay)
|
German Offenlegungsschrift Patent Document. Vol. #2618152,
|
|
rat
|
LD50
|
intraperitoneal
|
149mg/kg (149mg/kg)
|
|
Toxicology. Vol. 24, Pg. 335, 1982.
|
|
rat
|
LD50
|
oral
|
613mg/kg (613mg/kg)
|
|
Toxicology. Vol. 24, Pg. 335, 1982.
|
|
women
|
TDLo
|
intravenous
|
3400ug/kg/47M (3.4mg/kg)
|
behavioral: convulsions or effect on seizure threshold
cardiac: cardiomyopathy including infarction
|
British Medical Journal. Vol. 3, Pg. 698, 1972.
|
|
women
|
TDLo
|
oral
|
10mg/kg/5D-I (10mg/kg)
|
vascular: bp elevation not characterized in autonomic section
|
British Medical Journal. Vol. 1, Pg. 406, 1971.
|
|
women
|
TDLo
|
oral
|
30mg/kg (30mg/kg)
|
behavioral: coma
gastrointestinal: changes in structure or function of endocrine pancreas
gastrointestinal: decreased motility or constipation
|
Journal of Toxicology, Clinical Toxicology. Vol. 32, Pg. 425, 1994
|
